Celgene cuts 2020 outlook, Otezla sales disappoint; shares plunge

(Reuters) – Celgene Corp on Thursday reported third-quarter sales of its key psoriasis drug Otezla that badly missed expectations and significantly scaled down its 2020 targets for product sales and earnings, sending its shares tumbling 18 percent.


Source: Reuters Health News